Table 2b.
The association of patient and transplant characteristics with clinical outcomes in the univariate and multivariate analyses of relapse and NRM
| Relapse | NRM | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Cumulative Incidence at 1 Yr (95%CI) | P value* | HR (95%CI)† | P value† | Cumulative Incidence at 5 Yrs (95%CI) | P value* | HR (95%CI)† | P value† | |
|
| |||||||||
| Age at HSCT, yrs | |||||||||
| <50 | 207 | 0.295(0.234,0.358) | 0.021 | Reference | 0.014 | 0.213(0.159,0.272) | 0.013 | Reference | 0.001 |
| 50–59 | 136 | 0.191(0.130,0.262) | 0.90(0.62,1.30) | 0.258(0.188,0.335) | 1.72(1.13,2.62) | ||||
| 60+ | 139 | 0.158(0.103,0.224) | 0.54(0.35,0.82) | 0.295(0.220,0.374) | 2.04(1.37,3.03) | ||||
| Recipient sex | |||||||||
| Male | 261 | 0.222(0.174,0.274) | 0.51 | Reference | 0.28 | 0.252(0.200,0.307) | 0.33 | Reference | 0.61 |
| Female | 221 | 0.231(0.178,0.288) | 0.84(0.61,1.16) | 0.247(0.191,0.306) | 1.10(0.75,1.62) | ||||
| Female donor to male recipient | |||||||||
| Yes | 413 | 0.237(0.197,0.279) | 0.30 | Reference | 0.37 | 0.239(0.198,0.281) | 0.043 | Reference | 0.071 |
| No | 69 | 0.159(0.084,0.256) | 0.80(0.50,1.30) | 0.311(0.203,0.424) | 1.44(0.97,2.15) | ||||
| Disease Risk Index | |||||||||
| Low Risk | 22 | 0.0 (no events) | 0.002 | Reference | 0.002 | 0.273(0.108,0.469) | 0.56 | Reference | 0.66 |
| Intermediate Risk | 266 | 0.177(0.133,0.225) | 3.57(0.93,13.71) | 0.223(0.174,0.276) | 0.82(0.39,1.70) | ||||
| High Risk | 163 | 0.331(0.260,0.404) | 5.99(1.56,23.09) | 0.279(0.212,0.350) | 1.01 (0.48,2.15) | ||||
| Very High | 31 | 0.258(0.120,0.421) | 5.24(1.23,22.26) | 0.290(0.141,0.458) | 0.97(0.36,2.57) | ||||
| Conditioning Intensity | |||||||||
| RIC | 275 | 0.185(0.142,0.234) | 0.063 | Reference | 0.58 | 0.265(0.214,0.319) | 0.12 | Reference | 0.95 |
| MAC | 207 | 0.280(0.221,0.343) | 1.11(0.76,1.62) | 0.228(0.172,0.288) | 0.98(0.63,1.53) | ||||
| GVHD prophylaxis | |||||||||
| Tac/Siro | 313 | 0.236(0.191,0.285) | 0.87 | Reference | 0.69 | 0.254(0.206,0.304) | 0.18 | Reference | 0.048 |
| Tac/Siro/–ATG | 126 | 0.206(0.140,0.281) | 1.19(0.79,1.79) | 0.266(0.191,0.347) | 0.72(0.46,1.12) | ||||
| Tac/Siro/–ATG | 43 | 0.209(0.102,0.342) | 1.10(0.60,2.01) | 0.163(0.070,0.289) | 0.46(0.24,0.89) | ||||
| ABO blood group compatibility | |||||||||
| Compatible | 224 | 0.214(0.163,0.270) | 0.37 | Reference | 0.28 | 0.246(0.191,0.305) | 0.65 | Reference | 0.68 |
| Minor | 98 | 0.235(0.156,0.323) | 1.11(0.72,1.70) | 0.267(0.181,0.360) | 0.84(0.54,1.31) | ||||
| Major | 107 | 0.280(0.199,0.368) | 1.37(0.92,2.04) | 0.235(0.159,0.319) | 0.87(0.56,1.35) | ||||
| Bidirectional | 53 | 0.151(0.070,0.261) | 0.79(0.44,1.42) | 0.265(0.154,0.390) | 1.17(0.68,1.99) | ||||
| Donor/Recipient CMV serostatus | |||||||||
| D−/R− | 54 | 0.241(0.136,0.362) | 0.86 | Reference | 0.67 | 0.298(0.181,0.424) | 0.84 | Reference | 0.69 |
| D−/R+ | 214 | 0.243(0.188,0.302) | 1.09(0.64,1.85) | 0.246(0.189,0.306) | 0.75(0.44,1.27) | ||||
| D+/R− | 42 | 0.214(0.105,0.349) | 1.07(0.51,2.24) | 0.216(0.105,0.353) | 0.66(0.30,1.46) | ||||
| D+/R+ | 172 | 0.203(0.147,0.267) | 0.87(0.50,1.51) | 0.246(0.184,0.313) | 0.75(0.43,1.30) | ||||
| DQB1_status | |||||||||
| 2 | 446 | 0.222(0.185,0.262) | 0.71 | Reference | 0.69 | 0.250(0.211,0.292) | 0.51 | Reference | 0.33 |
| 1 | 36 | 0.278(0.143,0.431) | 1.13(0.61,2.12) | 0.229(0.105,0.382) | 0.73(0.39,1.37) | ||||
| Karnofsky performance status | |||||||||
| 90–100 | 286 | 0.199(0.155,0.248) | 0.053 | Reference | 0.21 | 0.261 (0.211,0.314) | 0.47 | Reference | 0.46 |
| 70–80 | 105 | 0.286(0.202,0.374) | 1.30(0.86,1.95) | 0.250(0.169,0.339) | 0.84(0.53,1.33) | ||||
| HCT comorbidity index | |||||||||
| 0 | 213 | 0.216(0.163,0.274) | 0.67 | Reference | 0.84 | 0.242(0.186,0.301) | 0.26 | Reference | 0.78 |
| 1–2 | 109 | 0.257(0.179,0.342) | 1.14(0.74,1.75) | 0.247(0.168,0.334) | 1.04(0.66,1.62) | ||||
| >2 | 70 | 0.186(0.104,0.285) | 1.05(0.64,1.74) | 0.325(0.216,0.440) | 1.19(0.73,1.93) | ||||
| HLA Match | |||||||||
| MUD | 351 | 0.234(0.191,0.279) | 0.49 | Reference | 0.31 | 0.217(0.175,0.262) | 0.038 | Reference | 0.002 |
| mMUD | 131 | 0.206(0.141,0.279) | 0.82(0.57,1.20) | 0.335(0.254,0.417) | 2.01(1.31,3.10) | ||||
*
Based on Gray’s test.
†
Based on the proportional subdistribution hazards model for competing risks adjusting for age, disease risk index, and HLA match for relapse; for age, female donor to male recipient, GVHD prophylaxis, and HLA match.